Top Page
Nanosonics Limited
(Sydney:NAN)
Nanosonics Limited (NAN) vs. iShares MSCI Australia ETF (EWA)
Nanosonics Limited Business Overview & Revenue Model
Nanosonics Limited Earnings Call Summary
Nanosonics Limited Financial Statement Overview
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 207.39M | 198.93M | 171.56M | 167.51M | 119.73M | 101.83M |
| Gross Profit | 160.05M | 155.66M | 133.99M | 125.66M | 86.15M | 74.91M |
| EBITDA | 29.06M | 31.82M | 21.72M | 29.50M | 7.86M | 15.75M |
| Net Income | 20.56M | 20.68M | 12.97M | 19.88M | 3.74M | 8.58M |
Balance Sheet | ||||||
| Total Assets | 279.25M | 272.48M | 237.34M | 226.07M | 193.24M | 164.57M |
| Cash, Cash Equivalents and Short-Term Investments | 159.83M | 161.29M | 129.55M | 112.16M | 94.51M | 96.03M |
| Total Debt | 9.88M | 7.69M | 9.30M | 10.72M | 11.71M | 2.49M |
| Total Liabilities | 59.56M | 62.57M | 55.14M | 62.22M | 54.55M | 29.01M |
| Stockholders Equity | 219.69M | 209.91M | 182.20M | 163.86M | 138.69M | 135.57M |
Cash Flow | ||||||
| Free Cash Flow | 24.38M | 35.26M | 20.27M | 19.74M | -271.00K | 5.93M |
| Operating Cash Flow | 29.40M | 43.98M | 22.78M | 23.31M | 6.70M | 7.32M |
| Investing Cash Flow | -5.00M | -8.71M | -2.36M | -3.54M | -6.90M | -1.38M |
| Financing Cash Flow | -7.59M | -3.30M | -3.01M | -2.71M | -1.97M | -1.03M |
Nanosonics Limited Technical Analysis
Nanosonics Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | AU$152.15M | 13.14 | 12.37% | 3.70% | -0.74% | 16.65% | |
68 Neutral | AU$982.84M | 47.86 | 10.32% | ― | 15.60% | 58.74% | |
63 Neutral | AU$131.16M | 16.59 | 12.35% | ― | 39.98% | -30.04% | |
56 Neutral | AU$210.74M | -127.08 | -2.01% | ― | 16.93% | 76.47% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | AU$80.85M | -58.89 | -4.28% | ― | 7.38% | 82.39% | |
44 Neutral | AU$97.09M | -5.15 | -31.98% | ― | 34.20% | -23.90% |
Nanosonics Limited Corporate Events
Nanosonics has presented its FY26 half-year results, highlighting continued growth in its installed base to 38,080 units and reinforcing its position in ultrasound probe reprocessing through the trophon platform. The company is also progressing the phased commercialisation of its CORIS system for endoscope reprocessing, which underscores its strategy to broaden its infection prevention portfolio and could strengthen its competitive positioning and value proposition for healthcare providers focused on patient safety.
The most recent analyst rating on (AU:NAN) stock is a Buy with a A$4.00 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.
Nanosonics reported first-half FY26 revenue of $102.2 million, up 9% year on year, with recurring and capital revenue each rising 9% and the installed base growing by 2,070 units to 38,080 devices. Operating margin expanded 27% to $8.5 million on disciplined cost control, though headline EBIT slipped 3% due to adverse foreign exchange movements despite double-digit growth on a constant currency basis.
North America remained the main growth driver with strong upgrade activity, including a 61% surge in North American upgrades to a record 980 units, largely trophon2 devices on volume-based pricing deals that are expected to support future recurring revenue. The half also saw the launch of next-generation trophon3 and the trophon2 Plus software upgrade package and regulatory milestones for the new CORIS system, positioning the company for further software-led value capture and expansion in infection prevention markets.
The most recent analyst rating on (AU:NAN) stock is a Buy with a A$4.00 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.
Nanosonics reported that its trophon installed base has reached 38,080 cumulative units, underscoring its strong position in ultrasound probe reprocessing and its role in protecting millions of patients each year. The company is now progressing the phased commercialisation of its CORIS platform, signalling an expansion into endoscope reprocessing that could significantly broaden its addressable market and reinforce its standing in the global infection prevention landscape.
The most recent analyst rating on (AU:NAN) stock is a Buy with a A$4.00 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.
Nanosonics reported half-year revenue of $102.2 million for the period ended 31 December 2025, a 9% increase on the prior corresponding period, reflecting continued sales growth across its infection prevention portfolio. However, profit before tax edged down 3% to $10.6 million and net profit after tax dipped 1% to $9.6 million, with basic earnings per share easing 2% to 3.17 cents.
The company’s net tangible assets per share rose 18.5% to 66.22 cents, indicating a stronger balance sheet despite the modest profit decline. Nanosonics did not declare a dividend for the half-year, consistent with the prior period, and confirmed there were no changes in control of entities, associates or joint ventures, underscoring a stable corporate structure as it continues to apply international reporting standards across its global subsidiaries.
The most recent analyst rating on (AU:NAN) stock is a Buy with a A$4.00 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.
UBS Group AG and its related entities have notified Nanosonics Limited that they have ceased to be a substantial shareholder in the company as of 28 January 2026, reducing their holding below the substantial shareholding threshold under Australian corporate law. The change in UBS’s position may alter Nanosonics’ institutional shareholder base and could impact perceptions of market support and liquidity for the stock, although no change in the company’s operations or governance was indicated in the notice.
The most recent analyst rating on (AU:NAN) stock is a Hold with a A$4.00 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.
Nanosonics Limited has announced it will release its FY26 half-year financial results on 24 February 2026, accompanied by an investor briefing hosted by CEO & President Michael Kavanagh and CFO Jason Burriss. The company is offering both an audio webcast and a separate conference call for investors, with the latter providing an opportunity for questions, and will make a recording of the event available on its website, underlining its ongoing efforts to maintain active engagement and transparency with the investment community.
The most recent analyst rating on (AU:NAN) stock is a Hold with a A$4.00 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.
Nanosonics Limited has appointed Sarah Butler as an independent non-executive director, effective 19 January 2026, strengthening its board with extensive international experience in healthcare, strategy, profitable growth and SaaS. Butler, a former senior partner at Booz Allen Hamilton, Booz & Company and PwC where she led a AU$2 billion Global Health practice, currently sits on several healthcare and insurance-related boards and will also join Nanosonics’ Innovation and Development Committee, a move expected to support the company’s innovation agenda and global expansion in infection prevention and endoscope reprocessing.
The most recent analyst rating on (AU:NAN) stock is a Hold with a A$4.00 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.
Nanosonics Limited issued a notification about a minor typographical correction in a previous announcement related to unquoted equity securities. The update clarified a discrepancy of 1,000 rights allocated to a key management personnel (KMP), reflecting an accurate allocation of 405,184 rights instead of 404,184. While the correction was minor, it demonstrates the company’s commitment to detail, transparency, and maintaining stakeholder trust.
The most recent analyst rating on (AU:NAN) stock is a Buy with a A$5.43 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.
Nanosonics Limited announced a change in Director Michael Kavanagh’s interest in securities, specifically acquiring 405,184 Performance Rights under the Nanosonics Equity Plan as part of the company’s long-term incentive (LTI) strategy for 2026. This update reflects the company’s commitment to aligning executive incentives with the long-term strategic and financial goals, indicating a focus on sustainable growth and value delivery for stakeholders.
The most recent analyst rating on (AU:NAN) stock is a Buy with a A$5.43 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.
Nanosonics Limited has announced the issuance of over two million unquoted performance rights as part of its employee incentive scheme. This move, aimed at motivating and retaining talent, highlights the company’s focus on aligning employee interests with its growth and strategic goals, with potential long-term benefits for stakeholders and its market position in the infection prevention sector.
The most recent analyst rating on (AU:NAN) stock is a Buy with a A$5.43 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.
Nanosonics Limited announced a change in the director’s interest, specifically involving Mr. Michael Kavanagh. The change pertains to the issuance of 59,233 Service Rights under the Nanosonics Equity Plan, reflecting the company’s ongoing commitment to aligning executive interests with shareholder value. This adjustment in securities is part of the company’s broader strategy to incentivize and retain key personnel, which could have implications for its operational focus and stakeholder engagement.
The most recent analyst rating on (AU:NAN) stock is a Buy with a A$5.43 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.
Nanosonics Limited has achieved significant regulatory milestones for its CORIS endoscope cleaning system, securing registrations in Australia, the EU, and the UK. These certifications enable the company to commence a Controlled Market Release in the UK, Ireland, and Australia starting January 2026, marking a crucial step in its commercialisation strategy and potentially strengthening its market position in infection prevention solutions.
The most recent analyst rating on (AU:NAN) stock is a Buy with a A$5.43 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.
Nanosonics Limited has announced an update regarding its ongoing on-market buy-back program. As of December 9, 2025, the company has repurchased a total of 355,909 ordinary fully paid securities, with an additional 51,000 securities bought back on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:NAN) stock is a Buy with a A$5.43 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.
Nanosonics Limited has announced a change in the director’s interest, specifically regarding Mr. Michael Kavanagh’s holdings. The change involves the exercise of 66,380 performance rights under the Nanosonics Omnibus Equity Plan, resulting in an increase in indirect ordinary shares held by Mr. Kavanagh. This adjustment reflects the company’s ongoing commitment to aligning leadership interests with shareholder value, potentially impacting stakeholder perceptions positively.
The most recent analyst rating on (AU:NAN) stock is a Buy with a A$5.43 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.
Nanosonics Limited has announced a daily update regarding its ongoing on-market buy-back program, with a total of 65,909 ordinary fully paid securities bought back on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure, potentially enhancing shareholder value and signaling confidence in its financial health.
The most recent analyst rating on (AU:NAN) stock is a Buy with a A$5.00 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.
Nanosonics Limited has announced an update on its ongoing on-market buy-back program, which involves the repurchase of its ordinary fully paid securities. As of the latest update, the company bought back 98,000 securities on the previous day, adding to a total of 192,000 securities repurchased before that. This buy-back initiative reflects the company’s strategic efforts to manage its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:NAN) stock is a Buy with a A$5.00 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.
Nanosonics Limited has announced the application for quotation of 152,842 ordinary fully paid securities on the Australian Securities Exchange (ASX). This move is part of an employee incentive scheme, potentially enhancing employee engagement and aligning their interests with company performance, which could positively impact the company’s operational dynamics and market positioning.
The most recent analyst rating on (AU:NAN) stock is a Buy with a A$5.00 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.
Nanosonics Limited has announced an update regarding its ongoing on-market buy-back program, with a total of 95,000 ordinary fully paid securities bought back on the previous day, adding to the 97,000 securities bought back before that. This buy-back initiative is part of the company’s efforts to manage its capital structure and potentially enhance shareholder value, reflecting a strategic move that may influence its market positioning and stakeholder interests.
The most recent analyst rating on (AU:NAN) stock is a Buy with a A$5.00 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.
Nanosonics Limited has announced an on-market buy-back of its ordinary fully paid securities, as indicated by the ASX security code NAN. This strategic financial move is likely aimed at optimizing the company’s capital structure and could have implications for shareholder value and market perception.
The most recent analyst rating on (AU:NAN) stock is a Buy with a A$5.00 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.
Nanosonics Limited has announced a daily on-market buy-back of its ordinary fully paid securities, as part of its capital management strategy. The buy-back will be conducted through Goldman Sachs, indicating a proactive approach to managing its share capital, which may positively influence investor confidence and market perception.
The most recent analyst rating on (AU:NAN) stock is a Buy with a A$5.00 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.
Nanosonics Limited has announced an update regarding its ongoing on-market buy-back program, with a total of 74,835 ordinary fully paid securities bought back on the previous day, contributing to a cumulative total of 425,624 securities repurchased. This buy-back initiative is part of the company’s strategy to optimize its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:NAN) stock is a Hold with a A$4.50 price target. To see the full list of analyst forecasts on Nanosonics Limited stock, see the AU:NAN Stock Forecast page.